Abstracts tagged "Bone density"

Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Marlies C. van der Goes¹, Johannes W.G. Jacobs¹, Maud S. Jurgens¹, Marije F. Bakker¹, Maaike J. van der Veen², Jacobine H. van der Werf³, Paco M.J. Welsing¹ and Johannes W.J. Bijlsma¹, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, ³Rheumatology, Diakonessenhuis, Utrecht, Netherlands
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Michael A. Bolognese¹, Edward Czerwinski², Henry G. Bone³, Sydney Bonnick⁴, Neil Binkley⁵, Alfred Moffett Jr.⁶, Suresh Siddhanti⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Rachel Wagman⁷, Jesse W. Hall⁷ and Chris Recknor¹⁰, ¹Bethesda Health Research Center, Bethesda, MD, ²Krakow Medical Center, Krakow, Poland, ³Michigan Bone and Mineral Clinic, Detroit, MI, ⁴Clinical Research Center of North Texas, Denton, TX, ⁵University of Wisconsin, Madison, WI, ⁶OB-GYN Associates of Mid Florida, PA, Leesburg, FL, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
Abstract Number: 1998 • 2012 ACR/ARHP Annual Meeting
Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
Michael A. Bolognese¹, Paul D. Miller², Jean-Yves Reginster³, Nathalie Franchimont⁴, Gerolamo Bianchi⁵, Roland Chapurlat⁶, Federico G. Hawkins⁷, David L. Kendler⁸, Beatriz Oliveri⁹, Jose R. Zanchetta¹⁰, Nadia Daizadeh⁴, Andrea Wang⁴, Rachel B. Wagman⁴ and Socrates Papapoulos¹¹, ¹Bethesda Health Research Center, Bethesda, MD, ²University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, CO, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵LELICOMAR - Div Reumatologia, Azienda Sanitaria Genovese, Genoa, Italy, ⁶Hôpital Edouard Herriot, Lyon, France, ⁷Hospital Universitario, Madrid, Spain, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Laboratorio Enfermedades Metabólicas Oseas, Hospital de Clínicas, INIGEM UBA-CONICET, Buenos Aires, Argentina, ¹⁰Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: During the first 3 years of denosumab treatment in FREEDOM, there were continued increases in bone mineral density (BMD) and a robust reduction in…
Abstract Number: 1970 • 2012 ACR/ARHP Annual Meeting
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Tristan Blackburn¹, Diantha Howard² and Edward S. Leib³, ¹Rheumatology, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ²Medicine, Vermont Center for Clinical and Translational Science, Burlington, VT, ³Medicine, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Predicting which individuals are at risk to experience a fracture and modify that risk is important in preventative health. The WHO’s Fracture Risk Assesment…
Abstract Number: 1958 • 2012 ACR/ARHP Annual Meeting
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Mario Jiménez-Hernández¹, Alma Rodríguez-Gallegos², Socorro Méndez-Martínez¹ and Aurelio Lopez-Colombo³, ¹Systemic Autoimmune Disease, HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Laboratorios Clínicos de Puebla, Puebla, Mexico, ³Research Departament, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Low bone mineral density (BMD) and osteoporosis may be significant complications in patients with systemic lupus erythematosus (SLE). Recent studies have shown that biologic therapy could…
Abstract Number: 1557 • 2012 ACR/ARHP Annual Meeting
What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center?
Marvin Vaishnani¹ and Feyrouz T. Al-Ashkar², ¹Rheumatic and Immunologic diseases, Cleveland Clinic,Lorain Institute, Lorain, OH, ²Rheumatic and Immunologic Diseases, Cleveland Clinic,Lorain Institute, Lorain, OH
Background/Purpose: Many younger women, < 65 years of age may have low bone mineral density (BMD) that remains undetected in clinical practice due to following…
Abstract Number: 1226 • 2012 ACR/ARHP Annual Meeting
Transition Time to Osteoporosis in Patients with Rheumatoid Arthritis
Jiwon Hwang¹, Joong Kyong Ahn², Ji Young Chai³, Hoon-Suk Cha¹, Jaejoon Lee¹ and Eunmi Koh¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis. Although bone mineral density (BMD) testing is routinely performed in patients with RA, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].